149.20
+0.30%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Merck KGaA
Its shares trade on XETRA under the ticker MRK.DE. It has been listed since 20 October 1995. It is a member of the DAX. In the fiscal year to 31 December 2025, it reported revenue of €21.10bn and net income of €2.61bn. At that date it held total assets of €52.10bn and shareholders' equity of €28.59bn.
Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. The company is headquartered in Darmstadt, Hessen. The firm operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Performance Materials business provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Oct 1995
- Employees
- 58,096
- Website
- merckgroup.com ↗
Leadership
Pay as last reported
- Mr. Michael KleinemeierIndependent Chairman of the Supervisory Board, since 2019€191,400
- Ms. Belen GarijoChairman of the Executive Board, Chief Executive Officer€8.3m
- Mr. Sascha HeldVice Chairman of the Supervisory Board, since 2019€143,900
- Ms. Helene Von RoederChief Financial Officer, Member of the Executive Board, since 2019€5.0m
- Ms. Khadija HammadaChief People Officer
- Mr. Florian SchraederHead of Investor Relations
- Mr. Danny Bar-zoharMember of the Executive Board, Chief Executive Officer - Pharmaceuticals Division
- Dr. Kai BeckmannMember of the Executive Board, Chief Executive Officer - Electronics€6.2m
- Mr. Jean-charles WirthMember of the Executive Board, Chief Executive Officer - the Life Science unit
- Ms. Carla KriwetIndependent Member of the Supervisory Board€56,400
- Ms. Barbara LambertIndependent Member of the Supervisory Board€148,400
- Mr. Stefan PalzerIndependent Member of the Supervisory Board€56,400
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 87
- Environment
- 99
- Social
- 99
- Governance
- 64
- Direct emissions (scope 1)
- 858,053 t
- Energy emissions (scope 2)
- 385,483 t
- Value chain emissions (scope 3)
- 4,482,938 t
- Women in the workforce
- 43.55228%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Merck has several key strengths that contribute to its success in the pharmaceutical industry. These strengths include:
Weaknesses
- Despite its strengths, Merck also faces certain weaknesses that may hinder its growth and competitiveness within the market. These weaknesses include:
Opportunities
- There are several opportunities that Merck can capitalize on to drive future growth and success. These opportunities include:
Threats
- Merck faces several threats that could potentially impact its market position and profitability. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.